Objective To investigate the correlation between self-rating and other-rating scales for symptom assessment and overall state assessment in depressive disorder patients treated with esketamine nasal spray. Methods Data were collected from 32 patients with depressive disorder who participated in a clinical trial of esketamine nasal spray treatment from June 2018 to February 2021 at Beijing Anding Hospital， Capital Medical University. All patients were randomly divided into the experimental group（ 18 cases） and the control group（ 14 cases） treated with esketamine nasal spray for 4 weeks and twice a week after the clinical trial of esketamine. Patients were assessed using the Montgomery-Asberg Depression Rating Scale（ MADRS）， Generalized Anxiety Disorder（ GAD-7）， Clinical Global Impression-Severity of Illness Scale（ CGI-S）， and the European Quality of Life-5 Dimensions 5 Levels（ EQ-5D-5L） on days 15（ D15） and 28（ D28） of the treatment period， and weeks 2（ W2）， 5（ W5）， and 8（ W8） of the follow-up period. The correlation of the amount of change was analyzed using Pearson's correlation and linear regression with repeated measures. Results In all subjects， the self-rating GAD-7 correlated moderately with the other-rating MADRS during the treatment and follow-up periods（ D28： r=0.420， P=0.017； W5： r=0.417， P=0.022； W8： r=0.568， P=0.001）. The amount of change in the self-rating EQ-5D-5L during the treatment period did not correlate statistically with the amount of change in the other-rating CGI-S（ D15： P=0.393， D28： P=0.187）， but showed a moderate correlation during the follow-up period（ W5： r=0.402， P=0.028； W8： r=0.473， P=0.008）. In the experimental group of ketamine administration， there was no correlation between the CGI-S reduction score of all scoring points and the EQ-5D- 5L addition rate（ P＞0.05）. In the placebo control group， there was a significant positive correlation between CGI-S score reduction and EQ-5D-5L score increase rate on the 15 th day of treatment， the 2 nd week， the 5 th week and the 8 th week of follow-up（ D15：r=0.740，P=0.003；W2：r=0.594，P=0.025；W5：r=0.675，P=0.016； W8：r=0.599，P=0.031）. Conclusions During treatment with esketamine nasal spray， self-rating of overall state in depressive disorder patients do not correlate significantly with other-rating， whereas there is a moderate correlation in the assessment of symptoms， and the combination of self-rating and other-rating contributes to a comprehensive assessment.